<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181947</url>
  </required_header>
  <id_info>
    <org_study_id>MDTEV20112009</org_study_id>
    <nct_id>NCT01181947</nct_id>
  </id_info>
  <brief_title>VALIANT CAPTIVIA Post-market Registry</brief_title>
  <acronym>VCOUS</acronym>
  <official_title>VALIANT CAPTIVIA Post-market Registry A Multi-center, Post-market, Non Interventional, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Valiant Thoracic Stent Graft has been preloaded on the new Captivia Delivery System
      (Captivia). This new delivery system was CE marked on September 14th, 2009 and was
      commercially released in the European Union on October 1st, 2009.

      The Valiant Thoracic Stent Graft with the Captivia Delivery System (Valiant Captivia) is
      designed to treat diseases of the descending thoracic aorta including but not limited to
      aneurysms and dissections.

      The purpose of the VALIANT CAPTIVIA Registry is to collect and evaluate mid term clinical
      performance data of the Valiant Captivia Thoracic Stent Graft System following OUS market
      approval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Use of controls

             1. This study is a post-market registry without using a control. All analyses will be
                descriptive in nature and no statistical comparisons are planned.

                Sample size

             2. There is no sample size calculation since this is not a hypothesis driven study;
                VALIANT CAPTIVIA has recruited 100 subjects and will follow these subjects through
                for approximately 36 months.

        2. Number of investigation sites and study duration

             1. 15 investigation sites in Europe and Turkey where the Valiant Captivia Thoracic
                Stent Graft System is commercially available have enrolled 100 subjects.

             2. There will be no minimum nor maximum number of enrolled subjects per investigation
                site.

             3. The sites' compliance with the clinical investigation plan will be assessed on an
                ongoing basis. In case of serious non-compliance, the sponsor may decide to stop
                subject enrolment in a site based on the assessment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    CIP was amended to include long-term FU but, not all sites accepted it so the nr. of pts
    participating in the extended FU will be small.
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>at 30 days, 12 months, 24 months and 36 months</time_frame>
    <description>technical success and freedom from
TAA diameter increase of stented segment (&gt;5mm compared to 1 mo),
Types I/III endoleak,
Aneurysm rupture,
Conversion to open surgery,
Stent graft occlusion,
Stent graft migration resulting in SAE or secondary intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical Success at Time of Initial Implant</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Technical success is defined as successful delivery and deployment of the stent graft (assessed intraoperatively). This is achieved by deployment of the Valiant Thoracic Stent Graft in the planned location with no unintentional coverage of the left subclavian artery, left common carotid artery and/or brachiocephalic artery and with the removal of the delivery system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>through 12 months</time_frame>
    <description>Serious Adverse Events (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACM and ARM</measure>
    <time_frame>at 30 days, 12 months, 24 months and 36 months</time_frame>
    <description>All-cause (ACM), Aneurysm related (ARM) and dissection related mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Aortic Aneurysm, Thoracic</condition>
  <arm_group>
    <arm_group_label>patients undergoing TEVAR</arm_group_label>
    <description>Those with a thoracic aortic aneurysm/dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TEVAR</intervention_name>
    <description>Thoracic endovascular aneurysm repair</description>
    <arm_group_label>patients undergoing TEVAR</arm_group_label>
    <other_name>Valiant Captivia stent graft system</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Valiant Thoracic Stent Graft with the Captivia Delivery System is indicated for
        treatment of diseases of the descending thoracic aorta including but not limited to
        aneurysms and dissections. The Valiant Thoracic Stent Graft is indicated for exclusion of
        the aneurysm, the false lumen or site of rupture and restoration of blood flow through the
        stent graft lumen. The device is intended for use in subjects who are candidates for
        conventional surgical repair, and in subjects who are not candidates for conventional
        surgical repair due to pre-existing risk factors.

        Study enrolment is open to subjects who in the opinion of the investigator are candidates
        for endovascular TAA repair with the Valiant Captivia Thoracic Stent Graft System according
        to the instructions for use (IFU).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age ≥ 18 years or minimum age as required by local regulations

          -  Indication for surgical repair of thoracic aortic aneurysms and/or thoracic aortic
             dissections with an thoracic endovascular stent graft in accordance with the
             applicable guidelines on endovascular interventions and the Instructions for Use of
             the Valiant Captivia Thoracic Stent Graft System

          -  Signed consent form ('Patient informed consent form' or 'Patient Data Release
             Authorization Form')

          -  Intention to implant the Valiant Captivia Thoracic Stent Graft System or having
             implanted the system within the last 3 months before subject enrollment

          -  Willingness and ability to comply with the CIP

        Exclusion criteria

          -  High probability of non-adherence to physician's follow-up requirements

          -  Participation in concurrent interventional trial which may confound study results

          -  Prior implantation of a thoracic stent graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Franziskus Hospital GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosella Fattori, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S.Orsola Malpighi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Vaquero Puerta, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Valladolid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Thompson, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. George's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Werner Jaschke, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Innsbruck</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yigit Goktay, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylül University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Heinz Orend, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omke Teebken, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Schmitz-Rixen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der J.W.Goethe-Universitat</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Steinbauer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Barmherzige Bruder Regensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Zangos, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Johann-Wolfgang-Goethe - Institut fur Diagnostische und Interventionelle Radiologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joep Teijink, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Heijmen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa Parildar, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatih Boyvat, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baskent University Ankara Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W.Goethe-Universitat</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang-Goethe - Institut fur Diagnostische und Interventionelle Radiologie</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Franziskus Hospital GmbH</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Bruder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic Hospital S.Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University Ankara Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Hospital</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George`s Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>January 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stent graft</keyword>
  <keyword>thoracic aorta</keyword>
  <keyword>dissection</keyword>
  <keyword>aneurysm</keyword>
  <keyword>TEVAR</keyword>
  <keyword>VALIANT</keyword>
  <keyword>CAPTIVIA</keyword>
  <keyword>endovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Undergoing TEVAR</title>
          <description>Those with a thoracic aortic aneurysm/dissection &gt;
&gt; TEVAR: Thoracic endovascular aneurysm repair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Undergoing TEVAR</title>
          <description>Those with a thoracic aortic aneurysm/dissection &gt;
&gt; TEVAR: Thoracic endovascular aneurysm repair</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" lower_limit="25" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Native aorta diameter</title>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="22" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Success</title>
        <description>technical success and freedom from
TAA diameter increase of stented segment (&gt;5mm compared to 1 mo),
Types I/III endoleak,
Aneurysm rupture,
Conversion to open surgery,
Stent graft occlusion,
Stent graft migration resulting in SAE or secondary intervention.</description>
        <time_frame>at 30 days, 12 months, 24 months and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAE</title>
        <description>Serious Adverse Events (SAE)</description>
        <time_frame>through 12 months</time_frame>
        <population>The primary and secondary endpoints will be reported descriptively.
By-gender and by-race data summaries for the primary endpoints, if appropriate, will be generated. Data from all study sites will be grouped together for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Undergoing TEVAR</title>
            <description>Those with a thoracic aortic aneurysm/dissection
TEVAR: Thoracic endovascular aneurysm repair</description>
          </group>
        </group_list>
        <measure>
          <title>SAE</title>
          <description>Serious Adverse Events (SAE)</description>
          <population>The primary and secondary endpoints will be reported descriptively.
By-gender and by-race data summaries for the primary endpoints, if appropriate, will be generated. Data from all study sites will be grouped together for analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="40" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACM and ARM</title>
        <description>All-cause (ACM), Aneurysm related (ARM) and dissection related mortality</description>
        <time_frame>at 30 days, 12 months, 24 months and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Technical Success at Time of Initial Implant</title>
        <description>Technical success is defined as successful delivery and deployment of the stent graft (assessed intraoperatively). This is achieved by deployment of the Valiant Thoracic Stent Graft in the planned location with no unintentional coverage of the left subclavian artery, left common carotid artery and/or brachiocephalic artery and with the removal of the delivery system</description>
        <time_frame>intraoperatively</time_frame>
        <population>The primary and secondary endpoints will be reported descriptively.
By-gender and by-race data summaries for the primary endpoints, if appropriate, will be generated. Data from all study sites will be grouped together for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Undergoing TEVAR</title>
            <description>Those with a thoracic aortic aneurysm/dissection &gt;
&gt; TEVAR: Thoracic endovascular aneurysm repair</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success at Time of Initial Implant</title>
          <description>Technical success is defined as successful delivery and deployment of the stent graft (assessed intraoperatively). This is achieved by deployment of the Valiant Thoracic Stent Graft in the planned location with no unintentional coverage of the left subclavian artery, left common carotid artery and/or brachiocephalic artery and with the removal of the delivery system</description>
          <population>The primary and secondary endpoints will be reported descriptively.
By-gender and by-race data summaries for the primary endpoints, if appropriate, will be generated. Data from all study sites will be grouped together for analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.4" upper_limit="100.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1. VCOUS</title>
          <description>Medtronic VCOUS</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Inflammatory Marker Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Stent-Graft Endoleak</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Graft Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular Bypass Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Compartment Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Respiratory Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vocal Cord Paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm Repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Aortic Rupture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vascular Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Medical Center or Investigator may, at his/her discretion, publish and/or present publicly the results of the work of Medical Center and/or Investigator performed under this Agreement. However, should Medical Center or Investigator contemplate publishing and/or presenting publicly such results, the Investigator shall provide copies of any abstracts, papers, or manuscripts to Medtronic for review at least 90 (ninety) days prior to submittal for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robin Heijmen</name_or_title>
      <organization>St. Antonius Ziekenhuis</organization>
      <phone>0031306092047</phone>
      <email>r.heijmen@antoniusziekenhuis.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

